Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Adding Caplyta to Portfolio

Jan 13, 2025, 03:57 PM

Johnson & Johnson has announced the acquisition of Intra-Cellular Therapies Inc. for approximately $14.6 billion, marking the largest biotech deal in over a year. The deal involves a cash payment of $132 per share, representing a 39% premium over Intra-Cellular's closing stock price on the previous Friday. The acquisition aims to bolster Johnson & Johnson's portfolio in the treatment of central nervous system disorders, including schizophrenia, through the addition of Intra-Cellular's drug Caplyta. The transaction is expected to be completed within the year. This move comes amidst a backdrop of increased M&A activity in the pharmaceutical sector, spurred by upcoming patent expirations and a potentially more favorable regulatory environment under the incoming Trump administration.